Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Five Guidances, FDA Overhauls Its Advisory Committee Policies

This article was originally published in The Gray Sheet

Executive Summary

FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5
Advertisement

Related Content

More To FDA AdComm Selection Process Than Meets The Eye
Advisory panel conflicts
Advisory panel conflicts
FDA Issues Draft Guidance On Advisory Panel Conflict Disclosures
FDA Issues Draft Guidance On Advisory Panel Conflict Disclosures
Advertisement
UsernamePublicRestriction

Register

MT026452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel